GAU1 and colorectal carcinoma: The in vitro oxaliplatin drug response data revealed that cancer cells overexpressing GAU1 or GALNT8 are more vulnerable to chemotherapy agents causing replication fork collapse, indicating GAU1/GALNT8 axis as a potential actionable target for the personalized medicine of CRC.